Real-world efficacy in clinical practice: An overall clinical success rate of 81% in elderly patients with CAP1
ZINFORO® was associated with high clinical cure rates across subgroups, including elderly patients with comorbidities and prior antibiotic usage.1,2
| Header | ||
|---|---|---|
| Header | Header | Header |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
*CAPTURE was a retrospective cohort study relating to the current treatment practice in the United States.1
CAPTURE was a multicentre study, assessing the contemporary use of ceftaroline fosamil in patients with CABP or acute bacterial skin and skin structure infection. Data were collected from 528 evaluable patients with CABP, from 39 sites in the United States, between August 2011 and April 2013.1
CABP, community-acquired bacterial pneumonia; CAP, community-acquired pneumonia; CAPTURE, Clinical Assessment Program and Teflaro® Utilization Registry.
References:
Safety profile consistent with other cephalosporins
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.